Related Experiment Videos
Apparent Michaelis-Menten kinetic parameters of phenytoin in pediatric patients
Insights
Concurrent anticonvulsants can alter phenytoin (PHT) pharmacokinetics in pediatric seizure patients. Increased Km, but not Vmax, was observed with more co-administered drugs, suggesting dosage adjustments based on Vmax may be beneficial.
Area of Science:
- Pharmacology
- Pediatric Neurology
- Clinical Pharmacy
Background:
- Phenytoin (PHT) is a widely used antiepileptic drug in pediatric populations.
- Understanding drug interactions affecting PHT pharmacokinetics is crucial for optimizing seizure control and minimizing toxicity.
- Michaelis-Menten kinetics describe drug metabolism, with Km and Vmax being key parameters.
Purpose of the Study:
- To investigate the impact of co-administered anticonvulsants on the Michaelis-Menten kinetic parameters (Km and Vmax) of phenytoin in pediatric patients.
- To determine if the number of concurrent anticonvulsants influences phenytoin's metabolic profile.
- To provide guidance on adjusting phenytoin dosage regimens in pediatric patients receiving multiple medications.
Main Methods:
- Retrospective analysis of 104 pediatric patients (0.5-16 years) with seizures.
- Estimation of individual Km and Vmax for phenytoin using steady-state plasma concentration and dose data.
- Comparison of kinetic parameters based on the number of co-administered anticonvulsant drugs.
Main Results:
- Phenytoin's Km tended to increase and become more variable with an increasing number of co-administered anticonvulsants.
- A significant increase in Km was observed in patients taking three or more concurrent anticonvulsants.
- Vmax was not significantly affected by co-administered anticonvulsants in older pediatric age groups.
- Additive inhibitory effects of co-administered drugs are suggested as the cause for increased Km.
Conclusions:
- Concurrent anticonvulsants can alter phenytoin's Michaelis-Menten kinetics in pediatric patients, primarily by increasing Km.
- Dosage adjustments for phenytoin in pediatric patients with inadequate seizure control or toxicity should consider the averaged Vmax within an age group, rather than Km.
- This finding aids in optimizing phenytoin therapy in children on multiple antiepileptic drugs.
Abstract:
In a retrospective study of 104 pediatric patients (0.5-16 yr) with seizures, the effects of concurrently administered anticonvulsants on Michaelis-Menten kinetic parameters of phenytoin were investigated. Individual kinetic parameters (Km and Vmax) for phenytoin were estimated from at least two reliable steady-state plasma concentration and dose data. Km tended to increase and to become more variable as the number of coadministered anticonvulsants increased. Significant difference was found in a group of patients taking three or more coadministered anticonvulsants. On the contrary, Vmax was not affected by those drugs in the higher age groups. Additive inhibitory rather than inductive effects of commonly used anticonvulsants appeared likely to cause an increase in Km. These observations suggest that dosage regimen adjustment of phenytoin based on the averaged Vmax in a given pediatric age group rather than the Km is recommended for a particular patient with inadequate therapeutic control of seizure or toxicity of this drug.